The Next PCSK-9 Pricing Debate: PBM Says Outcomes Data Should Mean Deeper Discount

Express Scripts expects to negotiate a lower price per patient for Amgen’s Repatha assuming the drug shows benefits in a 27,500-patient outcomes trial. Critics of the PBM and its practices, however, may help industry push back against the idea that greater benefit means lower prices.